OncoCyte (NYSE:OCX) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of OncoCyte (NYSE:OCX – Get Free Report) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

OncoCyte Stock Performance

Shares of NYSE:OCX opened at $0.22 on Tuesday. OncoCyte has a 12 month low of $0.20 and a 12 month high of $1.10.

Get OncoCyte alerts:

About OncoCyte

(Get Free Report)

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.

Featured Articles

• Five stocks we like better than OncoCyte
• Is It Time To Take Another Bite Of Chewy, Inc? 
• GreenPower Motor Company Shifts Into High Gear 
• Is the Microsoft Deal Driving Applied Optoelectronics 300% Gain?
• Can Unity Software Sustain The Momentum?
• Nvidia Invested $50 million into This AI Drug Discovery Biotech

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.